Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer conditions. The tender offer expired on 5 January 2026. The transaction involved purchasing all outstanding shares of Mersana at $25 per share in cash, along with one non-tradable contingent value right (CVR) per share. The CVR entitles shareholders to potential milestone payments of up to$30.25 per CVR in cash. The deal was first announced in November 2025 and had a total equity value o ...